Esophageal squamous cell carcinoma

This study tests whether adding tiragolumab to atezolizumab can help control esophageal cancer that hasn't grown after standard chemoradiotherapy. About 760 adults with inoperable esophageal squamous cell carcinoma will receive either the drug combination, atezolizumab alone, or …

This phase 3 trial tested whether adding two immunotherapy drugs, atezolizumab and tiragolumab, to standard chemotherapy could help people with advanced esophageal cancer live longer. About 461 participants received either the immunotherapy combo plus chemo or a placebo plus chem…

This trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responde…

This trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers lik…

This phase 2 trial tests whether adding the drug apatinib to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatin…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placeb…

This early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This study tested whether adding an experimental drug called LBL-007 to standard immunotherapy and chemotherapy helps shrink tumors better in people with advanced esophageal cancer that cannot be surgically removed. About 118 participants received either the three-drug combo or t…

This study tested a new surgical technique for esophageal cancer that avoids a large chest incision. 35 patients with early-stage cancer received this less invasive procedure. The goal was to see if it could lower complication rates while still effectively removing the cancer. Re…

This phase 3 trial tested whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside chemotherapy and radiation. The study me…

This phase 2 trial tested two experimental drugs, lomvastomig and tobemstomig, against the standard immunotherapy nivolumab in 190 people with advanced esophageal cancer that had worsened after chemotherapy. The drugs are bispecific antibodies designed to block two immune checkpo…

This study tested whether adding the immunotherapy drug pembrolizumab after standard chemoradiotherapy and surgery could prevent cancer recurrence in 26 patients with high-risk esophageal squamous cell carcinoma. Participants received cisplatin-based chemoradiotherapy followed by…

This phase 3 trial tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced esophageal cancer live longer or keep their cancer from growing. About 970 participants with inoperable or metastatic esophageal squamous ce…

This study looked at 120 people with esophageal cancer who had a type of surgery called McKeown esophagectomy. Half had the right gastric artery preserved, and half had it tied off. The goal was to see if preserving the artery lowers the chance of leaks or narrowing where the new…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other drugs in 90 people with advanced esophageal cancer that had already progressed after one prior treatment. The goal was to see if these combinations are safe and can shrink tumors …

This phase 2 trial tested whether adding the immunotherapy drug tislelizumab to chemotherapy and/or radiation before surgery could help completely eliminate esophageal cancer in 70 patients. The goal was to see if the tumor and all cancer cells in lymph nodes were gone at the tim…

This study looked at 200 people with advanced esophageal cancer to compare two treatments before surgery: immunotherapy combined with chemotherapy, versus chemotherapy plus radiation. Both treatments led to similar long-term survival rates. The immunotherapy combo may offer extra…

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This study tested whether a computer model could predict if esophageal cancer completely disappears after chemo-immunotherapy. Researchers reviewed medical records and CT scans from 363 patients who received standard treatment before surgery. The AI combined clinical data, radiom…

This study looked back at 387 patients with esophageal cancer to compare two chemotherapy drugs, nab-paclitaxel and paclitaxel, given before surgery. The goal was to see which drug leads to better outcomes like complete cancer removal. The study is completed, but results are not …

This study analyzed data from 414 esophageal cancer patients who received chemoimmunotherapy before surgery. Researchers developed a new 'bio-anatomical' staging system that combines tumor characteristics and immune response to better predict survival and guide post-surgery treat…

This study examines 300 esophageal cancer tissue and blood samples to classify tumors based on p53 gene mutations, protein expression, and immune response. Researchers will link these molecular subtypes to patient survival and treatment patterns. The goal is to see whether p53 fe…

This study looks back at medical records of people with esophageal squamous cell carcinoma who had immunotherapy and chemotherapy before surgery, followed by complete tumor removal. The goal is to see if adding radiotherapy after surgery, and how many lymph nodes were removed, af…

This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…

People with achalasia, a swallowing disorder, have a much higher risk of developing esophageal cancer. This study tested whether spraying a special dye (Lugol) during an endoscopy could help doctors find early signs of cancer (dysplasia) in 39 patients who had achalasia for over …

This completed study analyzed tumor and blood samples from 160 people with esophageal or rectal cancer. Researchers looked for genetic markers in the EGFR signaling pathway that might predict how well a patient responds to chemoradiotherapy given before surgery. The goal is to be…

This study analyzed medical records from 1197 patients in China with advanced esophageal cancer who received immunotherapy (anti-PD-1) plus chemotherapy as their first treatment. The goal was to see how long patients lived and how long the cancer stayed under control in everyday …

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…

This study looked at 577 patients who had surgery for esophageal cancer. Researchers compared two ways of giving nutrition after surgery: feeding through a tube placed directly into the small intestine (jejunostomy) versus a tube through the nose into the stomach (nasoenteric). T…

This study reviewed the medical records of over 3,100 people who had surgery to remove esophageal cancer at a major hospital in South Korea. The goal was to learn about common complications after surgery and how long patients lived afterward. The findings can help doctors improve…

This study looked at 605 patients with esophageal cancer who had minimally invasive surgery to remove their esophagus. Researchers compared those with and without type 2 diabetes to see if diabetes affected short-term complications and long-term survival. The goal is to understan…